At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, Radiation, and 5 other interventions for Cervical Cancer and 2 related conditions. Completed, enrolled 43 participants across 4 sites.
Detailed Summary
This is a Phase II study in patients with advanced and/refractory cervical cancer, endometrial carcinoma or uterine sarcoma. Patients will be treated with an immunomodulatory cocktail (Vitamin D, aspirin, Cyclophosphamide and Lansoprazole), followed by pembrolizumab, combined with radiation. In addition, patients will take Curcumin, a food supplement.
Study Details
Timeline
Interventions
Efficacy of the combined treatment
Efficacy of the combined treatment
Efficacy of the combined treatment
Efficacy of the combined treatment
Efficacy of the combined treatment
Efficacy of the combined treatment
Efficacy of the combined treatment